

Title (en)  
CRYSTAL FORMS OF BETA-NICOTINAMIDE MONONUCLEOTIDE

Title (de)  
KRISTALLFORMEN VON BETA-NICOTINAMID-MONONUKLEOTID

Title (fr)  
FORMES CRISTALLINES DE BÊTA-NICOTINAMIDE MONONUCLÉOTIDE

Publication  
**EP 3355895 A4 20190313 (EN)**

Application  
**EP 16852711 A 20160930**

Priority  
• US 201562236657 P 20151002  
• US 2016054776 W 20160930

Abstract (en)  
[origin: GB2542881A] The invention relates to crystalline forms of a  $\beta$ -nicotinamide mononucleotide (NMN), methods of their preparation, and related pharmaceutical preparations thereof. In one aspect, a crystalline compound of formula (I); In another aspect, a pharmaceutical composition comprising a crystalline compound of formula (I) and one or more pharmaceutically acceptable excipients. In yet another aspect, a method for preparing a crystalline compound of formula (I) comprising providing a mixture of a compound of formula (I) in a solvent and crystallising the compound of formula (I) from the mixture. The crystalline compound of formula (I) may be anhydrous or a solvate. Preferred solvents include dimethylsulfoxide, methanol and water. The solution may be brought to the point of supersaturation to precipitate out the compound of formula (I). This may be achieved by adding an anti-solvent or by cooling the solution to ambient temperature or lower.

IPC 8 full level  
**C07H 19/048** (2006.01); **A61K 31/7028** (2006.01); **A61K 31/7032** (2006.01); **A61K 31/7052** (2006.01)

CPC (source: EP GB IL KR US)  
**A61K 31/7052** (2013.01 - IL); **A61K 31/706** (2013.01 - GB IL); **A61P 43/00** (2018.01 - EP IL); **C07H 1/00** (2013.01 - IL KR); **C07H 19/048** (2013.01 - EP GB IL KR US); **A61K 31/7052** (2013.01 - EP US); **C07B 2200/13** (2013.01 - IL US)

Citation (search report)  
• [E] WO 2018047715 A1 20180315 - KYOWA HAKKO BIO CO LTD [JP]  
• [T] CAIRA M R ED - MONTCHAMP JEAN-LUC: "CRYSTALLINE POLYMORPHISM OF ORGANIC COMPOUNDS", TOPICS IN CURRENT CHEMISTRY; [TOPICS IN CURRENT CHEMISTRY], SPRINGER, BERLIN, DE, vol. 198, 1 January 1998 (1998-01-01), pages 163 - 208, XP001156954, ISSN: 0340-1022, DOI: 10.1007/3-540-69178-2\_5  
• See also references of WO 2017059249A1

Designated contracting state (EPC)  
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication)  
**GB 201608747 D0 20160629**; **GB 2542881 A 20170405**; **GB 2542881 A8 20170510**; **GB 2542881 B 20200101**; AU 2016331918 A1 20180510; AU 2016331918 B2 20211104; BR 112018006243 A2 20181016; CA 3000744 A1 20170406; CA 3000744 C 20240213; CN 108697722 A 20181023; CN 108697722 B 20210323; EA 037104 B1 20210205; EA 201890817 A1 20181031; EP 3355895 A1 20180808; EP 3355895 A4 20190313; EP 4272746 A2 20231108; EP 4272746 A3 20231115; IL 258276 A 20180531; IL 258276 B 20220701; JP 2018534265 A 20181122; JP 2021063081 A 20210422; JP 2022176979 A 20221130; KR 20180073582 A 20180702; MX 2018003656 A 20180430; US 10233208 B1 20190319; US 10392415 B2 20190827; US 10392416 B2 20190827; US 11059847 B2 20210713; US 2018282362 A1 20181004; US 2019085009 A1 20190321; US 2019225641 A1 20190725; US 2020157136 A1 20200521; US 2022098229 A1 20220331; WO 2017059249 A1 20170406; ZA 201802657 B 20240228

DOCDB simple family (application)  
**GB 201608747 A 20160518**; AU 2016331918 A 20160930; BR 112018006243 A 20160930; CA 3000744 A 20160930; CN 201680070598 A 20160930; EA 201890817 A 20160930; EP 16852711 A 20160930; EP 23197016 A 20160930; IL 25827618 A 20180321; JP 2018516685 A 20160930; JP 2020205773 A 20201211; JP 2022131443 A 20220822; KR 20187011822 A 20160930; MX 2018003656 A 20160930; US 2016054776 W 20160930; US 201615765325 A 20160930; US 201816133312 A 20180917; US 201916368052 A 20190328; US 201916454457 A 20190627; US 202117342694 A 20210609; ZA 201802657 A 20180420